McKessoc Corporation today praised the U.S. Department of Justice’s decision to exercise its authority to reduce opioid production if the agency believes a particular drug is highly diverted.
“We applaud this common-sense action by the Department of Justice. The annual opioid production quota determines the total amount of controlled substances that can be produced each year. That authority is significant as the nation struggles to address the current public health crisis around opioid addiction. This new rule calls on the Drug Enforcement Administration to carefully assess which drugs are being diverted – an important part of the effort to curb opioid misuse and abuse.”
In October 2017, McKesson called on the DEA to revise its annual production quota for opioids.
McKesson is deeply concerned by the impact the opioid epidemic is having on families and communities across the nation—and is committed to being part of the solution. The company has formed an independent foundation dedicated to addressing the crisis, to which McKesson contributed $100 million. The company is also advancing company initiatives aimed at preventing opioid abuse and has offered thoughtful public policy recommendations, including the Prescription Safety-Alert System (RxSAS) technology proposal.
To learn more about McKesson’s comprehensive efforts to address the opioid epidemic, please visit: www.McKesson.com/FightingOpioidAbuse.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.